Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, par value $.001
-
Shares outstanding
-
65.8M
-
Number of holders
-
127
-
Total 13F shares, excl. options
-
35.6M
-
Shares change
-
+1.07M
-
Total reported value, excl. options
-
$1.19B
-
Value change
-
+$60.3M
-
Put/Call ratio
-
1.14
-
Number of buys
-
70
-
Number of sells
-
-57
-
Price
-
$33.44
Significant Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) as of Q2 2021
164 filings reported holding CLDX - Celldex Therapeutics, Inc. - Common Stock, par value $.001 as of Q2 2021.
Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) has 127 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35.6M shares
of 65.8M outstanding shares and own 54.01% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (3.91M shares), Redmile Group, LLC (3.01M shares), BlackRock Inc. (2.7M shares), EVENTIDE ASSET MANAGEMENT, LLC (2.11M shares), STATE STREET CORP (2.09M shares), VANGUARD GROUP INC (1.97M shares), WELLINGTON MANAGEMENT GROUP LLP (1.96M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.82M shares), VR Adviser, LLC (1.24M shares), and ACUTA CAPITAL PARTNERS, LLC (987K shares).
This table shows the top 127 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.